Hematological cancers such as leukemia, lymphoma, and multiple myeloma have
traditionally been treated with chemo and radiotherapy approaches. Introduction of …

Leukemia is a malignancy initiated by uncontrolled proliferation of hematopoietic stem cell
from the B and T lineages, resulting in destruction of hematopoietic system. The …

Acute myeloid leukemia (AML) comprises a multifarious and heterogeneous array of
illnesses characterized by the anomalous proliferation of myeloid cells in the bone marrow …

Drug resistance is a key factor in the treatment failure of acute myeloid leukemia (AML).
Nuclear factor E2-related factor 2 (Nrf2) plays a crucial role in tumor chemotherapy …

Fms-like tyrosine kinase 3 (FLT3) is often overexpressed or constitutively activated by
internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations in acute …

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by high rate of
therapy resistance. Since the cell of origin can impact response to therapy, it is crucial to …

Progress is occurring at a dizzying rate across all leukemias. Since the authors' review of the
topic in Cancer in 2018, numerous discoveries have been made that have improved the …

While the introduction of T cell-based immunotherapies has improved outcomes in many
cancer types, the development of immunotherapies for both adult and pediatric AML has …

Objectives Historically, patients with leukaemia and invasive fusariosis (IF) have
experienced poor outcomes in the setting of persistent immunosuppression. Herein, we …

Background There is a male predominance of acute myeloid leukemia (AML) incidence, but
survival data are conflicting. The objective of this study is to carry out a comprehensive …